| |
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
Today’s Big NewsOct 7, 2024 |
|
De-risk clinical trials with Foresight CLARITY’s ultra-sensitive MRD detection. Foresight CLARITY is IUO-ready for prospective trials through our CLIA-registered central lab. Learn more about Foresight CLARITY™️. 
|
|
| By Gabrielle Masson As summer heat turns to cool winds, hopes that this year would bring widespread industry relief have dissipated, with quarterly layoffs evening out to similar levels as the same time last year. |
|
|
|
By Kevin Dunleavy Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers Squibb’s schizophrenia treatment Cobenfy (KarXT) has had an unusual odyssey and one that may serve as instructive for future drug discovery. |
By Conor Hale The former Fierce 15 winner has priced some 6.7 million shares in the range of $14 to $16, for a proposed total market value of about $505.4 million. |
By Nick Paul Taylor A phase 3 trial of Scholar Rock’s spinal muscular atrophy candidate has hit its primary endpoint, sparking a 200%-plus premarket surge in the biotech’s stock price. Investors went wild despite the higher dose falling short of the targeted efficacy and Scholar Rock making no mention of a key secondary goal. |
|
Wednesday, October 16, 2024 | 2pm ET / 11am PT Join experts as they delve into the distinct strategies required for developing ADCs and RIT, focusing on how medical imaging can accelerate clinical trials and drug approval. Register now to gain practical insights into optimizing clinical trials and advancing cancer therapies through cutting-edge imaging techniques. 
|
|
By Fraiser Kansteiner After winning a first-in-class nod for its two-drug inhaler Airsupra last January, AstraZeneca is bolstering the rescue treatment’s clinical package with new data showing it can cut the risk of asthma exacerbations regardless of patients’ disease severity. |
By Fraiser Kansteiner Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said. Natco and Mylan—which is now part of Viatris—are working together on the development of a generic version of the massively popular diabetes drug. |
By Darren Incorvaia The Nobel Assembly at the Karolinska Institute has taken a liking to RNA. The committee has awarded two American biologists the 2024 Nobel Prize in Physiology or Medicine for their discovery of microRNA, the small RNA molecules that regulate genes, one year after the prize went to scientists who conducted foundational work on mRNA vaccines. |
By Conor Hale MARAbio Systems derived its name from a particular pattern of antibodies carried by the child’s mother, which research has shown can react with proteins found in the developing brain. |
By Nick Paul Taylor AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal, which covers a potential rival to an Eli Lilly prospect, positions AstraZeneca to run combination studies with an existing candidate it sees as a $5 billion-a-year blockbuster. |
By Zoey Becker The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026. |
By Gabrielle Masson Taking the mat is Judo Bio, an Atlas Venture-backed biotech armed with $100 million to develop oligonucleotide medicines targeting the kidney. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote. |
|
|---|
|
|
|
Wednesday, October 23, 2024 | 11am ET / 8am PT Large, deeply characterized patient cohorts are one of the most promising data resources today for understanding disease biology and developing new medicines. Join us as we explore how this data is driving the next generation of pharmaceutical development. Learn how to leverage genetic research in today's highly competitive landscape. Register now. 
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
